CoChat

Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment

Open access
Fineberg, Naomi A, Apergis-Schoute, Annemieke M, Vaghi, Matilde M, Banca, Paula, Gillan, Claire M, Voon, Valerie, Chamberlain, Samuel R, Cinosi, Eduardo, Reid, Jemma, Shahper, Sonia, Bullmore, Edward T, Sahakian, Barbara J, Robbins, Trevor W · 2018 · International Journal of Neuropsychopharmacology
Cited by 183

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

Compulsions are repetitive, stereotyped thoughts and behaviors designed to reduce harm. Growing evidence suggests that the neurocognitive mechanisms mediating behavioral inhibition (motor inhibition, cognitive inflexibility) reversal learning and habit formation (shift from goal-directed to habitual responding) contribute toward compulsive activity in a broad range of disorders. In obsessive compulsive disorder, distributed network perturbation appears focused around the prefrontal cortex, caudate, putamen, and associated neuro-circuitry. Obsessive compulsive disorder-related attentional set-shifting deficits correlated with reduced resting state functional connectivity between the dorsal caudate and the ventrolateral prefrontal cortex on neuroimaging. In contrast, experimental provocation of obsessive compulsive disorder symptoms reduced neural activation in brain regions implicated in goal-directed behavioral control (ventromedial prefrontal cortex, caudate) with concordant increased activation in regions implicated in habit learning (presupplementary motor area, putamen). The ventromedial prefrontal cortex plays a multifaceted role, integrating affective evaluative processes, flexible behavior, and fear learning. Findings from a neuroimaging study of Pavlovian fear reversal, in which obsessive compulsive disorder patients failed to flexibly update fear responses despite normal initial fear conditioning, suggest there is an absence of ventromedial prefrontal cortex safety signaling in obsessive compulsive disorder, which potentially undermines explicit contingency knowledge and may help to explain the link between cognitive inflexibility, fear, and anxiety processing in compulsive disorders such as obsessive compulsive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyx088

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 86

  1. Adams, 1982, Variations in the sensitivity of instrumental responding to reinforcer devaluation, Q J Exp Psychol, 34B, 77, 10.1080/14640748208400878 · DOI · Paper page
  2. Afshar, 2014, Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial, J Res Med Sci, 19, 976
  3. Afshar, 2012, N-acetylcysteine add-on treatment in refractory obsessive compulsive disorder: a randomized, double-blind, placebo-controlled trial, J Clin Psychopharmacol, 32, 797, 10.1097/JCP.0b013e318272677d · DOI · Paper page
  4. American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, 10.1176/appi.books.9780890425596 · DOI · Paper page
  5. Arnsten, 2011, Prefrontal cortical organization and function: implications for externalizing disorders, Biol Psychiatry, 69c, 1131, 10.1016/j.biopsych.2011.03.010 · DOI
  6. Atmaca, 2011, Serotonin transporter gene polymorphism implicates reduced orbito-frontal cortex in obsessive-compulsive disorder, J Anxiety Disord, 25, 680, 10.1016/j.janxdis.2011.03.002 · DOI
  7. Balleine, 2010, Human and rodent homologies in action control: corticostriatal determinant of goal-directed and habitual action, Neuropsychopharmacology, 35, 48, 10.1038/npp.2009.131 · DOI · Paper page
  8. Batistuzzo, 2015, Visuospatial memory improvement after gamma ventral capsulotomy in treatment refractory obsessive-compulsive disorder patients, Neuropsychopharmacology, 40, 1837, 10.1038/npp.2015.33 · DOI
  9. Berlin, 2011, Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder, J Clin Psychiatry, 72, 716, 10.4088/JCP.09m05266gre · DOI · Paper page
  10. Bloch, 2012, Effects of ketamine in treatment-refractory obsessive-compulsive disorder, Biol Psychiatry, 72, 964, 10.1016/j.biopsych.2012.05.028 · DOI · Paper page
  11. Bruno, 2012, Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo controlled study, J Psychopharmacol, 26, 1456, 10.1177/0269881111431751 · DOI · Paper page
  12. Cha, 2014, Circuit-wide structural and functional measures predict ventromedial prefrontal cortex fear generalization: implications for generalized anxiety disorder, J Neurosci, 34, 4043, 10.1523/JNEUROSCI.3372-13.2014 · DOI · Paper page
  13. Chamberlain, 2013, Noradrenergic modulation of cognition: therapeutic implications, J Psychopharmacol, 27, 694, 10.1177/0269881113480988 · DOI · Paper page
  14. Costa, 2017, Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder, J Clin Psychiatry, 78, e766, 10.4088/JCP.16m11101 · DOI · Paper page
  15. Dalley, 2011, Impulsivity, compulsivity, and top-down cognitive control, Neuron, 69, 681, 10.1016/j.neuron.2011.01.020 · DOI · Paper page
  16. Darrow, 2016, Identificationof two heritable cross disorder endophenotypes for Tourette syndrome, Am J Psychiatry
  17. Daw, 2011, Model-based influences on humans’ choices and striatal prediction errors, Neuron, 69, 1204, 10.1016/j.neuron.2011.02.027 · DOI · Paper page
  18. Dell’Osso, 2008, Escitalopram in the treatment of impulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase, J Clin Psychiatry, 69, 452, 10.4088/JCP.v69n0316 · DOI · Paper page
  19. Dell’Osso, 2013, The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of obsessive compulsive spectrum disorders (ICOCS) ICOCS group, Eur Neuropsychopharmacol, 23, 865, 10.1016/j.euroneuro.2013.05.004 · DOI
  20. Denys, 2013, Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder, Eur Neuropsychopharmacol, 23, 1423, 10.1016/j.euroneuro.2013.05.012 · DOI · Paper page
  21. De Sousa, 2008, An open-label pilot study of naltrexone in childhood-onset trichotillomania, J Child Adolesc Psychopharmacol, 18, 30, 10.1089/cap.2006.0111 · DOI · Paper page
  22. de Vries, 2016, Tic-relatedvstic-freeobsessive-compulsivedisorder: clinical picture and 2-year natural course, J Clin Psychiatry, 77, 1240, 10.4088/JCP.14m09736 · DOI
  23. de Wit, 2009, Associative theories of goal-directed behavior: a case for animal-human translational models, Psychol Res, 73, 463, 10.1007/s00426-009-0230-6 · DOI · Paper page
  24. Ducasse, 2014, D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis, Psychopharmacology, 231, 3765, 10.1007/s00213-014-3516-3 · DOI
  25. Fineberg, 2013, The obsessive compulsive and related disorders research network. Manifesto for a European research network into obsessive-compulsive and related disorders, Eur Neuropsychopharmacol, 23, 561, 10.1016/j.euroneuro.2012.06.006 · DOI
  26. Fineberg, 2013, A Prospective Population-Based Cohort Study Of The Prevalence, Incidence And Impact Of Obsessive-Compulsive Symptomatology, Int J Psychiatry Clin Pract, 17, 170, 10.3109/13651501.2012.755206 · DOI · Paper page
  27. Fineberg, 2015, The neuropsychology of obsessive-compulsive personality disorder: a new analysis, CNS Spectr, 17, 1
  28. Fineberg, 2016, Mapping compulsivity: cognitive domains, neural circuitry and treatment, Int J Neuropsychopharmacology, 19, 47
  29. Frost, 2010, Stuff: compulsive hoarding and the meaning of things
  30. Grant, 2010, A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response, J Clin Psychopharmacol, 30, 396, 10.1097/JCP.0b013e3181e617a1 · DOI · Paper page
  31. Grant, 2014, Clinical guide to obsessive compulsive and related disorders, 10.1093/med/9780199977758.001.0001 · doi:10.1093/med/9780199977758.001.0001
  32. Grant, 2014, The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study, J Clin Psychopharmacol, 34, 134, 10.1097/JCP.0000000000000037 · DOI · Paper page
  33. Groenewegen, 2000, The prefrontal cortex and the integration of sensory, limbic and autonomic information, Prog Brain Res, 126, 3, 10.1016/S0079-6123(00)26003-2 · DOI · Paper page
  34. Groenewegen, 2003, Does an imbalance between the dorsal and ventral striatopallidal systems play a role in Tourette’s syndrome? A neuronal circuit approach, Brain Dev, 25, 3, 10.1016/S0387-7604(03)90001-5 · DOI
  35. Haghighi, 2013, In a double-blind, randomized and placebo controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD), Psychopharmacology (Berl), 228, 633, 10.1007/s00213-013-3067-z · DOI
  36. Hellriegel, 2016, Is “not just right experience” (NJRE) in obsessive-compulsive disorder part of an autistic phenotype, CNS Spectr, 11, 1
  37. Hesse, 2011, The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disoder, Int J Neuropsychopharmacol, 14, 606, 10.1017/S1461145710001604 · DOI · Paper page
  38. Hoexter, 2013, Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioraltherapyinobsessive-compulsivedisorder, Eur Neuropsychopharm, 23, 569, 10.1016/j.euroneuro.2012.06.014 · DOI
  39. Hollander, 2016, The cost and impact of compulsivity: a research perspective, Eur Neuropsychopharmacol, 26, 800, 10.1016/j.euroneuro.2016.02.006 · DOI
  40. Hugo, 1999, Functional brain imaging in obsessive-compulsive disorder secondary to neurological lesions, Depress Anxiety, 10, 129, 10.1002/(SICI)1520-6394(1999)10:3<129::AID-DA7>3.0.CO;2-B · doi:10.1002/(sici)1520-6394(1999)10:3<129::aid-da7>3.0.co;2-b
  41. Jefferies-Sewell, 2016, Cognitive dysfunction in body dysmorphic disorder: new implications for nosological systems and neurobiological models, CNS Spectr, 30, 1
  42. Khalkhali, 2016, Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Iran J Psychiatry, 11, 104
  43. Kolevzon, 2006, Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability, J Clin Psychiatry, 67, 407, 10.4088/JCP.v67n0311 · DOI · Paper page
  44. Koran, 2005, Mirtazapine for obsessive-compulsive disorder: An open trial followed by double-blind discontinuation, Journal of Clinical Psychiatry, 66, 515, 10.4088/JCP.v66n0415 · DOI · Paper page
  45. Koran, 2005, Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder, J Clin Psychiatry, 66, 353, 10.4088/JCP.v66n0312 · DOI · Paper page
  46. Lopes, 2015, JAMA Psychiatry, 72, 1258, 10.1001/jamapsychiatry.2015.0673 · DOI
  47. Marras, 2016, Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11, CNS Spectr, 12, 1
  48. Mataix-Cols, 2006, Common and distinct neural correlates of obessive-compulsive and related disorders, Psychiatr Clin North Am, 29, 391, 10.1016/j.psc.2006.02.006 · DOI
  49. Matsumoto, 2010, Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C] DASB PET study, Neuroimage, 49, 121, 10.1016/j.neuroimage.2009.07.069 · DOI · Paper page
  50. Menzies, 2008, Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited, Neurosci Biobehav Rev, 32, 525, 10.1016/j.neubiorev.2007.09.005 · DOI · Paper page
  51. Monzani, 2012, A twin study of body dysmorphic concerns, Psychol Med, 42, 1949, 10.1017/S0033291711002741 · DOI · Paper page
  52. Morris, 2013, Habit reversal training in trichotillomania: guide for the clinician, Expert Rev Neurother, 13, 1069, 10.1586/14737175.2013.827477 · DOI · Paper page
  53. Mowla, 2016, Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial, J Clin Psychopharmacol, 36, 720, 10.1097/JCP.0000000000000592 · DOI
  54. Mowla, 2010, Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial, CNS Spectr, 15, 613, 10.1017/S1092852912000065 · DOI · Paper page
  55. Monzani, 2012, A twin study of body dysmorphic concerns, Psychol Med, 42, 1949, 10.1017/S0033291711002741 · DOI · Paper page
  56. Odlaug, 2011, A neurocognitive comparison of cognitive flexibility and response inhibition in gamblers with varying degrees of clinical severity, Psychol Med, 41, 2111, 10.1017/S0033291711000316 · DOI · Paper page
  57. Park, 2016, ADHD and executive functioning deficits in OCD youths who hoard, Psychiatr Res, 82, 141, 10.1016/j.jpsychires.2016.07.024 · DOI
  58. Paydary, 2016, N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial, J Clin Pharm Ther, 41, 214, 10.1111/jcpt.12370 · DOI · Paper page
  59. Phillips, 2010, Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V, Depr Anxiety, 27, 528, 10.1002/da.20705 · DOI · Paper page
  60. Pitman, 1987, Clinical comparison of Tourette’s disorder ad obsessive compulsive disorder, Am J Psychiatry, 144, 1166, 10.1176/ajp.144.9.1166 · DOI · Paper page
  61. Prado, 2008, Sensory phenomena in obsessive-compulsive disorder and tic disorders: a review of the literature, CNS Spectr, 13, 425, 10.1017/S1092852900016606 · DOI · Paper page
  62. Rashid, 2015, Adjunctive antipsychotic in the treatment of body dysmorphic disorder - a retrospective naturalistic case note study, Int J Psychiatry Clin Pract, 19, 84, 10.3109/13651501.2014.981546 · DOI
  63. Rauch, 1998, Neuroimaging in obsessive-compulsive disorder and related disorder
  64. Rauch, 2000, Volume reduction in the caudate nucleus following stereotactic placement of lesions in the anterior cingulate cortex in humans: a morphometric magnetic resonance imaging study, J Neurosurg, 1019, 10.3171/jns.2000.93.6.1019 · DOI · Paper page
  65. Rauch, 2001, Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods, Adv Neurol, 85, 207
  66. Reghunandanan, 2015, Pathogenesis. In: Obsessive-compulsive and related disorders, 13, 10.1093/med/9780198706878.003.0003 · DOI
  67. Reghunandanan, 2015, Psychotherapy, an integrated approach, 62, 10.1093/med/9780198706878.003.0005 · doi:10.1093/med/9780198706878.003.0005
  68. Reghunandanan, 2015, Pharmacotherapy and somatic treatments. In: Obsessive-compulsive and related disorders, 37, 10.1093/med/9780198706878.003.0004 · doi:10.1093/med/9780198706878.003.0004
  69. Reimold, 2007, Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity – a [11C] DASB PET study, J Neural Transm (Vienna), 114, 1603, 10.1007/s00702-007-0785-6 · DOI
  70. Rosenberg, 2001, Brain anatomy and chemistry may predict treatment response in pediatric obsessive-compulsive disorder, Int J Neuropsychopharmacol, 4, 179, 10.1017/S1461145701002401 · DOI · Paper page
  71. Rothbart, 2013, Pharmacotherapy for trichotillomania, Cochrane Database Syst Rev, 11, CD007662
  72. Sachdev, 2017, Pharmacological Treatments for Obsessive Compulsive and Related Disorders - A Trans-Diagnostic Perspective. In: A Transdiagnostic Approach to Obsessions, Compulsions and Related Phenomena
  73. Sarris, 2015, N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study, CNS Drugs, 29, 801, 10.1007/s40263-015-0272-9 · DOI
  74. Saxena, 2014, Venflaxine extended release treatment of hoarding disorder, Int Clin Psychopharmacol, 29, 266, 10.1097/YIC.0000000000000036 · DOI
  75. Senço, 2015, Transcranial direct current stimulation in obsessive-compulsive disorder: emerging clinical evidence and considerations for optimal montage of electrodes, Expert Rev Med Devices, 12, 381, 10.1586/17434440.2015.1037832 · DOI · Paper page
  76. Stein, 1994, Neuropsychiatry of obsessive-compulsive disorder
  77. Steketee, 2011, The Oxford handbook of obsessive compulsive and spectrum disorders
  78. Uhm, 2016, Comparison of a peer facilitated support group to cognitive behavior therapy: study protocol for a randomised controlled trial for hoarding disorder, Contemp Clin Trials, 50, 98, 10.1016/j.cct.2016.07.018 · DOI
  79. Vaghi, 2016, Specific frontostriatal circuits for impaired cognitive flexibility and goal-directed planning in obsessive-compulsive disorder: evidence from resting-state functional connectivity, Biol Psychiatry, 81, 708, 10.1016/j.biopsych.2016.08.009 · DOI · Paper page
  80. Van Ameringen, 2010, A randomised, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania, J Clin Psychiatry, 71, 1336, 10.4088/JCP.09m05114gre · DOI · Paper page
  81. Voon, 2015, Motivation and value influences in the relative balance of goal-directed and habitual behaviors in obsessive-compulsive disorder, Transl Psychiatry, 5, e670, 10.1038/tp.2015.165 · DOI · Paper page
  82. Worbe, 2016, Valence-dependent influence of serotonin depletion on model-based choice strategy, Mol Psychiatry, 21, 624, 10.1038/mp.2015.46 · DOI · Paper page
  83. World Health Organisation, 1992, ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines
  84. World Health Organisation, 2010, International statistical classification of diseases and related health problems
  85. Yucel, 2007, Functional and biochemical alternations of the medial frontal cortex in obsessive-compulsive disorder, Arch Gen Psychiatry, 64, 946, 10.1001/archpsyc.64.8.946 · DOI · Paper page
  86. Zungu-Dirwayi, 1999, Are musical obsessions a temporal lobe phenomenon, J Neuropsychiat Clin Neurosci, 11, 398, 10.1176/jnp.11.3.398 · DOI

Cited by

See all 183

Metadata

Authors
Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., Banca, P., Gillan, C. M., Voon, V., Chamberlain, S. R., Cinosi, E., Reid, J., Shahper, S., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W.
Venue
International Journal of Neuropsychopharmacology
Published
2017-09-23
Volume
21
Issue
1
Pages
42-58
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2756509241
Cited by
183
References
89
FWCI
26.55
Type
journal article
Language
en
Open access
gold
Funders
Wellcome Trust (110049/Z/15/Z)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.